Aurinia Pharmaceuticals Inc (AUPH)

[moosedogger]

I missed the lack of a rapid steroid taper- wonder if the trial designers didn't appreciate the value of that back in 2012?

The other oddity is that it's a 2 year trial while AURORA is a 1 year. That also seems like a poor design choice as Aurinia stresses that the key with an LN flare is to get the patients into remission (or as close as they can get) as rapidly as possible to prevent kidney damage.

Definitely looking good here- really liking the team, the plan, the execution, etc., etc.

They have an excellent chance to do something really special. Still waiting for the market to recognize that.

Thanks for your input/feedback